Device and methods for targeted tissue drug delivery

• US 10,118,014 B2
• Filed: 09/09/2013
• Issued: 11/06/2018
• Est. Priority Date: 09/11/2012
• Status: Active Grant

• Current Assignee: Native Cardio, Inc.
• Original Assignee: Native Cardio, Inc.
• Inventors: Kim, Young D., Pergolizzi, Joseph V., Johnson, Scot
• Primary Examiner(s): Hulbert, Amanda
• Assistant Examiner(s): Patel, Natasha
• Application Number:
  US14/427,607
• Publication Number:
  US 20150224281A1
• Time in Patent Office: 1,884 Days
• CPC Class Codes: A61M 19/00 Local anaesthesia syringes therefor A61M5/00; Hypothermia A61M5/42 takes precedence; cooling blood in a bypass of the arterial system A61M1/36
• CPC Class Codes: A61M 2025/0004 having two or more concentrically arranged tubes for forming a concentric catheter system
• CPC Class Codes: A61M 25/0023 by the form of the lumen, e.g. cross-section, variable diameter
• CPC Class Codes: A61N 1/046 Specially adapted for shock therapy, e.g. defibrillation
• CPC Class Codes: A61N 1/0476 Array electrodes (including any electrode arrangement with more than one electrode for at least one of the polarities)
• CPC Class Codes: A61N 1/0587 Epicardial electrode systems; Endocardial electrodes piercing the pericardium
• CPC Class Codes: A61N 1/0595 Temporary leads
• CPC Class Codes: A61N 1/0597 Surface area electrodes, e.g. cardiac harness

Abstract

Representative embodiments of the present invention provide for novel, minimally invasive implantable devices and methods for targeted tissue drug delivery of cardiovascular drugs.

Claims

1. A minimally invasive device for treatment of a patient, the device comprising:

a. at least one inner catheter comprising at least one drug delivery channel located within the inner catheter, the at least one drug delivery channel adapted to deliver a drug to a cardiac surface of the patient;

b. an outer catheter substantially surrounding the at least one inner catheter;

c. a plurality of electrically conductive elements within the inner catheter and surrounding the drug delivery channel and extending to be also located at a substantially distal portion of the device; and

d. at least one membrane interconnecting the plurality of electrically conductive elements at the substantially distal portion of the device, wherein the membrane is adapted to deform with the beating of the heart,

wherein the plurality of electrically conductive elements interconnecting with the membrane at the substantially distal portion of the device are arranged in a flower-like arrangement fanning out from a central hub,

wherein the plurality of electrically conductive elements are adapted to provide defibrillation energy to a cardiac surface of the patient,

wherein the device is effective for treating chronic atrial fibrillation.

2. The device according to claim 1, wherein at least one adhesive material is provided on an underside of the membrane.

3. The device according to claim 2, wherein the at least one adhesive material comprises at least one adhesive polymer.

4. The device according to claim 1, comprising at least one anti-arrhythmic drug.

5. The device according to claim 4, wherein the at least one anti-arrhythmic drug is selected from the group consisting of procainamide, amiodarone, a combination of procainamide and at least one other anti-arrhythmic drug, a combination of amiodarone and at least one other anti-arrhythmic drug, and a combination of procainamide, amiodarone and at least one other anti-arrhythmic drug.

6. The device according to claim 1, comprising at least one anesthetic drug.

7. The device according to claim 6, wherein the anesthetic drug is selected from the group consisting of procaine, lidocaine, a combination of procaine and at least one other anesthetic drug, a combination of lidocaine an at least one other anesthetic drug, and a combination of procaine, lidocaine, and at least one other anesthetic drug.

8. A method of treating a patient suffering from an abnormal cardiac rhythm, the method comprising:

implanting a minimally invasive device in a patient in need of treatment for chronic atrial fibrillation, the device comprising;

a. at least one inner catheter comprising at least one drug delivery channel located within the inner catheter, the at least one drug delivery channel delivering a drug to a cardiac surface of the patient;

b. an outer catheter substantially surrounding the at least one inner catheter;

c. a plurality of electrically conductive elements within the inner catheter and surrounding the drug delivery channel and extending to be also located at a substantially distal portion of the device; and

d. at least one membrane interconnecting the plurality of electrically conductive elements at the substantially distal portion of the device, wherein the membrane is adapted to deform with the beating of the heart,

wherein the plurality of electrically conductive elements interconnecting with the membrane at the substantially distal portion of the device are arranged in a flower-like arrangement fanning out from a central hub,

wherein the plurality of electrically conductive elements provide defibrillation energy to a cardiac surface of the patient,

wherein the distal portion of the device further comprises at least one drug release site for delivery of at least one drug to the cardiac surface of the patients,

wherein the method is effective for treating chronic atrial fibrillation.

9. The method according to claim 8, wherein at least one adhesive material is provided on an underside of the membrane.

10. The method according to claim 9, wherein the at least one adhesive material comprises at least one adhesive polymer.

11. The method according to claim 8, further comprising delivering at least one anti-arrhythmic drug through the device.

12. The method according to claim 11, wherein the at least one antiarrhythmic drug is selected from the group consisting of procainamide, amiodarone, a combination of procainamide and at least one other anti-arrhythmic drug, a combination of amiodarone and at least one other anti-arrhythmic drug, and a combination of procainamide, amiodarone and at least one other anti-arrhythmic drug.

13. The method according to claim 8, further comprising delivering at least one anesthetic drug through the device.

14. The method according to claim 13, wherein the anesthetic drug is selected from the group consisting of procaine, lidocaine, a combination of procaine and at least one other anesthetic drug, a combination of lidocaine and at least one other anesthetic drug, and a combination of procaine, lidocaine, and at least one other anesthetic drug.

15. The method according to claim 8, wherein the patient is treated for ventricular fibrillation.